美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

MRNA期权收益策略ETF-YieldMax

15.45

+0.05000.32%

盘后：15.680.2300+1.49%19:43 EDT

成交量：18.91万

成交额：293.33万

市值：8,312.06万

市盈率：- -

高：15.84

开：15.43

低：15.28

收：15.40

52周最高：27.50

52周最低：13.60

股本：538.00万

流通股本：538.00万

量比：1.85

换手率：3.51%

股息：15.87

股息率：102.72%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Replimune的皮肤癌药物在美国获批迎来第三次机会

美国食品药品监督管理局（FDA）顾问委员会投票赞成建议新冠疫苗针对XFG变异株

美国FDA顾问投票支持建议2026-27年度新冠疫苗以Jn.1谱系Xfg变异株为靶点

Moderna公司计划于八月中旬前备妥2026-27年度推荐新冠疫苗组分供应

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/MRNY"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MRNY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNY\",,,,,undefined,":{"symbol":"MRNY","market":"US","secType":"STK","nameCN":"MRNA期权收益策略ETF-YieldMax","latestPrice":15.45,"timestamp":1780084800000,"preClose":15.4,"halted":0,"volume":189073,"hourTrading":{"tag":"盘后","latestPrice":15.68,"preClose":15.45,"latestTime":"19:43 EDT","volume":1329,"amount":20629.1281,"timestamp":1780098194851,"change":0.23,"changeRate":0.014887,"amplitude":0.014887},"delay":0,"changeRate":0.0032467532467531776,"floatShares":5379974,"shares":5379974,"eps":0,"marketStatus":"休市中","change":0.05,"latestTime":"05-29 16:00:00 EDT","open":15.43,"high":15.84,"low":15.28,"amount":2933307.5447055004,"amplitude":0.036364,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":15.4,"sharesOutstanding":6479974,"nav":15.42,"aum":82959199.08,"dividendRate":1.027156,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":15.469,"preClose":15.4,"latestTime":"09:29 EDT","volume":1990,"amount":30703.70801,"timestamp":1780061373627,"change":0.069,"changeRate":0.004481,"amplitude":0.023779},"postHourTrading":{"tag":"盘后","latestPrice":15.68,"preClose":15.45,"latestTime":"19:43 EDT","volume":1329,"amount":20629.1281,"timestamp":1780098194851,"change":0.23,"changeRate":0.014887,"amplitude":0.014887},"volumeRatio":1.8510328387489157,"impliedVol":0.4764,"impliedVolPercentile":0.428},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNY\",,,,,undefined,":{"symbol":"MRNY","floatShares":5379974,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.8510328387489157,"shares":5379974,"dividePrice":15.869567,"high":15.84,"amplitude":0.036364,"preClose":15.4,"low":15.28,"week52Low":13.6,"pbRate":"--","week52High":27.5,"institutionHeld":0,"latestPrice":15.45,"eps":0,"divideRate":1.027156,"volume":189073,"delay":0,"ttmEps":0,"open":15.43,"prevYearClose":14.7,"prevWeekClose":15.46,"prevMonthClose":15.64,"prevQuarterClose":18.57,"fiveDayClose":15.49,"twentyDayClose":15.64,"sixtyDayClose":21.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MRNY\",params:#limit:5,,,undefined,":[{"date":"2026-05-28","symbol":"MRNY","amount":0.2357,"announcedDate":"2026-05-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-28","defaultRemindTime":1779975000000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-29","payableDate":"2026-05-28","currency":"USD","dateTimestamp":1779940800000,"payDate":"2026-05-29"},{"date":"2026-05-21","symbol":"MRNY","amount":0.1838,"announcedDate":"2026-05-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-21","defaultRemindTime":1779370200000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-22","payableDate":"2026-05-21","currency":"USD","dateTimestamp":1779336000000,"payDate":"2026-05-22"},{"date":"2026-05-14","symbol":"MRNY","amount":0.2387,"announcedDate":"2026-05-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-14","defaultRemindTime":1778765400000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-14","currency":"USD","dateTimestamp":1778731200000,"payDate":"2026-05-15"},{"date":"2026-05-07","symbol":"MRNY","amount":0.1551,"announcedDate":"2026-05-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-07","defaultRemindTime":1778160600000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-08","payableDate":"2026-05-07","currency":"USD","dateTimestamp":1778126400000,"payDate":"2026-05-08"},{"date":"2026-04-30","symbol":"MRNY","amount":0.2176,"announcedDate":"2026-04-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-30","defaultRemindTime":1777555800000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-01","payableDate":"2026-04-30","currency":"USD","dateTimestamp":1777521600000,"payDate":"2026-05-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MRNY\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-07","recordDate":"2023-12-08","paymentDate":"2023-12-13","value":0.413,"currency":"USD"},{"executeDate":"2024-01-05","recordDate":"2024-01-08","paymentDate":"2024-01-09","value":2.6542,"currency":"USD"},{"executeDate":"2024-02-07","recordDate":"2024-02-08","paymentDate":"2024-02-09","value":0.5944,"currency":"USD"},{"executeDate":"2024-03-06","recordDate":"2024-03-07","paymentDate":"2024-03-08","value":1.131,"currency":"USD"},{"executeDate":"2024-04-04","recordDate":"2024-04-05","paymentDate":"2024-04-08","value":0.7832,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MRNY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MRNY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2639622049","title":"Replimune的皮肤癌药物在美国获批迎来第三次机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2639622049","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639622049?lang=zh_cn&edition=fundamental","pubTime":"2026-05-29 20:12","pubTimestamp":1780056779,"startTime":"0","endTime":"0","summary":"更新版 4-Replimune的皮肤癌药物在美国获批迎来第三次机会重启申请的消息传出后，股价暴涨86%《华尔街日报》称白宫敦促卫生官员重新审查FDA的驳回决定 Replimune称FDA将优先审查重新提交的申请分析师指出，FDA立场转变的动因尚不明确重写第1段，在第4-5段中补充《华尔街日报》报道的细节，第6段尝试获取评论，最后为股价及要点。路透5月30日 - Replimune公司周五表示，在与美国监管机构达成协议后，计划于未来数日第三次申请其实验性皮肤癌药物的批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4S42613K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1291159041.SGD","IE0009355771.USD","SRPU","LU0432979614.USD","IE0002141913.USD","LU1718418525.SGD","LU0225771236.USD","LU2125154935.USD","LU1261432733.SGD","LU0868494617.USD","BK4007","LU1868836914.USD","BK4559","BK4588","LU1571399168.USD","LU1093756325.SGD","LU0237698245.USD","LU2242652126.USD","LU0114720955.EUR","LU0306806265.USD","MRNA","LU1430594728.SGD","LU0061475181.USD","SRPT","LU1868836757.USD","IE00BJJMRZ35.SGD","REPL","BK4534","BK4568","LU1983299246.USD","MRNX","MRNY","LU1670710661.SGD","LU1868836591.USD","BMY","LU1670711040.USD","LU1032466523.USD","IE00BFXG1179.USD","BK4501","LU1868837300.USD","LU1074936037.SGD","LU1883839398.USD","BK4532","BK4551","LU1670711123.USD","LU0321505868.SGD","LU2242646821.SGD","BK4548","LU0096364046.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639961878","title":"美国食品药品监督管理局（FDA）顾问委员会投票赞成建议新冠疫苗针对XFG变异株","url":"https://stock-news.laohu8.com/highlight/detail?id=2639961878","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639961878?lang=zh_cn&edition=fundamental","pubTime":"2026-05-29 02:30","pubTimestamp":1779993056,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）顾问委员会投票赞成建议新冠疫苗针对XFG变异株路透5月28日 - 美国食品药品监督管理局（FDA）的咨询委员会周四投票通过了一项建议，即2026-2027年度免疫接种活动所使用的新冠疫苗应针对占主导地位的JN.1谱系XFG变异株。九名委员会成员中有八人投票支持该建议，一人弃权。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nL4T4251VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","MRNX","LU0058720904.USD","SG9999002232.USD","LU1066051498.USD","IE00BBT3K403.USD","BK4548","BK4592","IE00B19Z3581.USD","LU0234572021.USD","LU0456855351.SGD","LU1023059063.AUD","BK4551","BK4581","LU1066053197.SGD","SG9999003800.SGD","SG9999011175.SGD","IE0002270589.USD","SGXZ57979304.SGD","IE000M9KFDE8.USD","SG9999013999.USD","IE00BLSP4239.USD","BK4501","LU0225284248.USD","BK4534","LU0225771236.USD","LU0321505439.SGD","SG9999002224.SGD","BK4532","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","LU0868494617.USD","PFE","SG9999001176.SGD","BK4568","LU0321505868.SGD","LU0306806265.USD","LU1057294990.SGD","BK4588","LU0306807586.USD","BK4533","LU1883839398.USD","LU1894683348.USD","MRNA","LU1894683264.USD","SG9999001176.USD","LU0170899867.USD","LU0985481810.HKD","BK4599","BK4139","BK4007","BK4585","LU0289739699.SGD","MRNY","BK4550","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139235440","title":"美国FDA顾问投票支持建议2026-27年度新冠疫苗以Jn.1谱系Xfg变异株为靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1139235440","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139235440?lang=zh_cn&edition=fundamental","pubTime":"2026-05-29 02:28","pubTimestamp":1779992883,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局的疫苗顾问小组已投票支持一项建议，即在2026-2027年度的新冠疫苗接种活动中，应将疫苗的靶点更新为当前流行的Jn.1谱系Xfg变异株。这一决定标志着公共卫生机构在应对病毒持续演变方面迈出了关键一步。相关企业可能需要据此调整其疫苗成分，以符合新的公共卫生指导。随着病毒变异，疫苗的定期更新已成为新常态，以确保其防护效力。最终决定权仍在FDA，但通常其会采纳顾问委员会的建议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","IE00B3T34201.USD","LU1066051498.USD","BK4532","LU1057294990.SGD","LU0122379950.USD","SG9999001176.SGD","SGXZ57979304.SGD","LU0058720904.USD","MRNY","SG9999002224.SGD","BK4550","LU0289739699.SGD","BK4585","IE00BLSP4239.USD","BK4548","BK4592","BK4581","BK4568","BK4534","SG9999001176.USD","BK4007","LU0321505439.SGD","IE00BBT3K403.USD","BK4547","BK4588","LU0306807586.USD","SG9999002232.USD","LU0306806265.USD","IE0002270589.USD","LU0985481810.HKD","MRNX","PFE","IE00B19Z3B42.SGD","BK4139","IE00BLSP4452.SGD","SG9999013999.USD","LU0321505868.SGD","LU1066053197.SGD","SG9999003800.SGD","LU1894683264.USD","LU1894683348.USD","LU0225771236.USD","IE000M9KFDE8.USD","LU0868494617.USD","MRNA","BK4501","BK4599","BK4533","NVAX","LU0234572021.USD","LU1023059063.AUD","BK4551","LU1883839398.USD","SG9999011175.SGD","IE00B19Z3581.USD","LU0456855351.SGD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158347106","title":"Moderna公司计划于八月中旬前备妥2026-27年度推荐新冠疫苗组分供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1158347106","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158347106?lang=zh_cn&edition=fundamental","pubTime":"2026-05-28 20:19","pubTimestamp":1779970758,"startTime":"0","endTime":"0","summary":"根据最新简报文件披露，Moderna公司已做好充分准备，预计将在八月中旬之前完成针对2026-27年度推荐新冠疫苗组分的生产供应部署。这一时间节点对于确保秋季疫苗接种计划的顺利推进具有关键意义，显示出该公司在应对公共卫生需求方面的前瞻性布局能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4533","BK4534","BK4548","BK4139","BK4585","MRNY","BK4532","BK4588","BK4501","MRNX","MRNA","BK4551"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":23,"pageCount":1,"totalSize":90,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MRNY\",params:#limit:6,delay:false,,,undefined,":[]}}